1.4 months, HR 0.37, one-sided p < 0.0001) and updated analysis showed a trend towards better median OS in the experimental arm (10.3 vs. 7.5 months, HR 0.79, p = 0.09), which may have been impacted by crossover from the placebo to treatment group [ 10 , 38 ].
3 G; LCN2 levels showed a trend for significance ( p = 0.09)].
Notably, frontline treatment with CPX-351 showed a trend toward inferior OS compared with Ven-HMA (HR 1.3 95% CI 0.9–1.8, p = 0.09, Supplemental Fig. 4).
In multivariable regression models adjusting for baseline clinical differences, the interaction between midbrain SBR and LID status for the 4‐year putamen SBR showed a trend‐level association ( p = 0.09, q = 0.15).
None of the differences between these groups reached statistical significance, although patients who underwent labral debridement alone showed a trend toward increased OA progression ( P = .09).
Patients were also stratified using TIR, with largely similar findings.Participants with eGDR <8mg/kg -1 .min -1 showed a trend towards higher mean basal PS expression, but not P-selectin, compared with higher eGDR (PS 1216±1152 vs 458±163, p=0.09 ) .
Compared with the CON group, ETEC challenges showed a trend towards the increased transcription expression of LOC110259329 ( Fig. 6 C, P = 0.09), lower transcription expression of PLA2G2A , and higher transcription expression of PLB1 , whereas the L. plantarum L47 and inulin pretreatment enhanced the transcription expression of PLA2G2A and CYP3A29 upon ETEC challenges ( Fig. 6A– B and D, P < 0.05).
A subgroup analysis of FOLFOX-treated patients showed a trend ( P = 0.09) toward longer OS in cetuximab-treated patients versus bevacizumab-treated patients, with OS 30.1 versus 26.9 months, respectively.
Univariate analysis showed a trend towards increased risk of e-irAEs for women (OR, 1.39; 95% CI, 0.95–2.02; p = 0.09), although it was not statistically significant in multivariate analysis ( p = 0.8).
1.0 ( p = 0.004), where-as LApre-systole volume showed a trend with HR 1.15 ( p = 0.09).
22-26 Furthermore, mutational profiling of pretreatment biopsy samples with matched gene expression data showed a trend toward more non-CR patients in the TP53 mutant group ( P = .09) ( Figure 6G ).
Although not significant, the MLC group also showed a trend toward shorter overall survival (OS) (median, 29 vs 64 months, respectively; 95% CI, 21.2-84.9; log-rank P = .09).
Symptom Burden and Physical Functioning Pain scores (EORTC QLQ-C30) showed a trend toward improvement (mean: 30.00 ± 28.52 to 22.00 ± 23.12, p = 0.090), but the change was not statistically significant.
In univariate analysis, the use of statins was implicated with CIPN ( p = 0.03–0.04 with different assessments) and diabetes showed a trend ( p = 0.09) in the development of CIPN.
In addition, DM + HC + CKD showed a trend towards an increase in liver fat deposition ( p = 0.09), which correlated positively with plasma levels of total cholesterol ( r 2 = 0.519, p < 0.05) and correlated inversely with ASAT ( r 2 = 0.466, p < 0.05).
CV-ST was significantly increased in the har40 (p = 0.02) and showed a trend in wei40 (p = 0.09) compared to the normg trials.
While Cox regression did not reveal statistically significant associations with graft survival, CD3 − PAX8 − CD16 + CD57 + cells showed a trend toward increased risk (HR = 2.73, p = 0.09).
But it showed a trend of increasing (quadratic, P = 0.09) the laying rate with the highest in the 6% ramie group.
As shown previously for other strains [ 21 ], female gWAT exhibited higher respiration for complex I ( log 2 FC = 1.2, p = 0.03 ) and a trend toward higher complex IV activity ( log 2 FC = 2.0, p = 0.09 ), while in iWAT, males showed a trend toward higher activity for both complex I ( log 2 FC = 0.85, p = 0.09 ) and complex IV ( log 2 FC = 0.80, p = 0.19 ; Figure 1 D).
However, low serum AMH women had significantly greater live birth rates ( p < 0.05) and showed a trend towards greater clinical pregnancy rates compared to women in the average and high AMH groups ( p = 0.09).
In quadriceps, chymotrypsin-like activity was significantly increased in CHF compared with sham by 79% ( P < 0.05; Figure 5 A), whereas trypsin-like activity only showed a trend towards increased activity in CHF animals by 48% ( P = 0.09; Figure 5 C).
When adjusting for APOE -ε4 status in the Cox regression, PHS (status) showed a significant effect on clinical progression ( P = 0.002), with higher polygenic hazard increasing the risk of conversion, while APOE -ε4 burden showed a trend over APOE -ε4 status ( P = 0.09).
The severity of CINP at the end of chemotherapy, according to PI-NRS, showed a trend to significance between males and females (7 [range: 6–9] vs. 7 [range: 5–8], respectively; p = 0.09).
Both HLA-C/-B KIR-ligand- and HLA-A-A3/-A11 KIR-ligand-incompatible UCBT showed a trend to improved LFS ( P =0.09 and P =0.13, respectively).
It also showed a trend for increased CMAP amplitude in Sod1 −/− mice ( p = 0.09, paired t-test , data not shown), whereas it did not alter CMAP assessment of muscle function in WT mice.